Clinical Trials Browser

Phase 1/2 × Select Advanced Solid Tumors × Antibodies, Monoclonal × Clear all

NCT04262466 2026-03-06

Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors

Phase 1/2 Active not recruiting

Other solid neoplasm

Select Advanced Solid Tumors